Amicus Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Welcome, everyone, to the 40th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan, joined by Cable Smith, Malcolm Kuno and Priyanka Grover from the team. Our next presenting company is Amicus Therapeutics. And presenting on behalf of this company, we have CEO, John Crowley, and incoming CEO, Bradley Campbell. (Operator Instructions)
With that, John, Brad, take it away.
Great. I'll go ahead and begin Anupam. Thank you, and thanks, everybody, for joining. This is going to be a very exciting year for Amicus as we're poised to launch our second medicine in the last several years for people living with rare diseases. So we'll come to that on the first slide here, I'll just reference that Bradley, and I will be making forward-looking statements. And then on the next slide, if we fast forward to Slide 4, you'll see a snapshot of Amicus and who we are today.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |